contact us jpkrencn



あなたはここにいる:ホーム > お知らせ > 企業動向 > Medicilon and Xiling...

Medicilon and Xiling Lab formed a strategic partnership

著者:Medicilon   アップロード:2022-07-05  閲読回数:

On June 17, 2022, Shanghai Medicilon Inc. and Xiling Lab signed a strategic collaboration agreement on innovative drug research and development services in Tianfu Life Science Park.

Medicilon is committed to helping clients to accelerate the development of new drugs with efficient and cost-effective R&D services.  With the formation of this strategic partnership, both parties will leverage their respective advantages to achieve resource sharing and win-win collaboration to promote the early launch of more clinical drugs.

About Xiling Lab
Xiling Lab is a cutting-edge drug research and development company headquartered in China and operating globally. Driven by innovation and collaboration, Xiling Lab provides safe, effective and accessible high-quality medicines to patients in China and around the world.  Xiling Lab is committed to building an internationally leading platform for small molecule drug concept validation, contrast agent drug development and catalytic technology.  Xiling Lab also develops innovative medicines for the diagnosis and treatment of oncology, gastrointestinal diseases, and ophthalmic diseases.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional?drug discovery contract research organizations (CRO)?in China.  Over the years, Medicilon keeps improving their services in?biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

上の:Medecine assisted | BIOTAI bispecific neutralizing antibody drug BAT2022 was approved clinically.

下に:AI empowers the research and of innovative drugs, Medicilon and Langrui have reached collaboration